新华制药(000756) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was CNY 1,789,023,665.87, representing a 28.79% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was CNY 99,053,729.45, an increase of 16.19% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 95,189,524.32, up 44.11% from the previous year, driven by expanded sales opportunities[8]. - The basic earnings per share for Q3 2022 was CNY 0.15, a 7.14% increase year-on-year[5]. - The diluted earnings per share remained stable at CNY 0.14, with no change compared to the previous year[5]. - The company reported a net profit margin improvement, with net profit increasing alongside revenue growth, although specific figures were not disclosed in the provided content[24]. - The net profit for the current period is 303,195,955.06, an increase from 297,252,235.38 in the previous period, representing a growth of approximately 1.3%[27]. - The total profit for the current period is 334,607,994.44, compared to 340,012,441.58 in the previous period, showing a decrease of about 1.2%[27]. - The operating profit for the current period is 338,081,275.06, slightly down from 344,208,270.78 in the previous period, indicating a decline of around 1.8%[27]. - The total comprehensive income for the current period is 281,032,140.69, compared to 249,238,018.45 in the previous period, indicating an increase of about 12.8%[27]. Assets and Liabilities - The total assets at the end of Q3 2022 reached CNY 8,194,604,106.80, a growth of 11.76% compared to the end of the previous year[5]. - Total assets reached ¥8,194,604,106.80, compared to ¥7,332,033,657.98 at the beginning of the year, indicating a growth of 11.8%[20]. - Total liabilities increased to ¥4,001,250,874.08 from ¥3,680,888,823.85, marking a rise of 8.7%[23]. - The company's equity attributable to shareholders rose to ¥3,972,802,737.29 from ¥3,467,941,567.45, an increase of 14.6%[23]. - Cash and cash equivalents increased to ¥1,212,766,900.26 from ¥744,662,302.34, representing a growth of 62.8%[19]. - Cash flow from operating activities for the current period is 233,819,696.10, compared to 230,422,146.43 in the previous period, reflecting a marginal increase of about 1.3%[30]. - The cash and cash equivalents at the end of the period amount to 1,049,450,512.26, an increase from 675,142,439.65 in the previous period, representing a growth of approximately 55.4%[33]. Costs and Expenses - Total operating costs amounted to ¥5,118,017,176.96, up 11.4% from ¥4,594,778,972.14 year-on-year[24]. - Research and development expenses were ¥258,495,146.14, reflecting an increase from ¥247,397,181.53 in the previous year[24]. - The company received government subsidies amounting to CNY 6,084,676.54 during the reporting period[7]. Cash Flow - The company reported a net cash flow from operating activities of CNY 233,819,696.10, which is a 1.47% increase year-to-date[5]. - Cash flow from financing activities shows a net increase of 376,795,259.04, a significant improvement from a net outflow of -100,041,207.71 in the previous period[33]. - The company received cash from investment activities amounting to 16,115,180.00, up from 9,993,236.39 in the previous period, marking an increase of approximately 61.5%[30]. Inventory and Borrowings - Inventory decreased to ¥970,173,470.97 from ¥1,027,539,968.72, a decline of 5.6%[19]. - Short-term borrowings increased to ¥382,448,776.17 from ¥269,455,217.71, reflecting a rise of 42.0%[20]. Return on Equity - The weighted average return on equity was 2.52%, a slight decrease of 0.01 percentage points compared to the previous year[5].